Purified fish oils could help treat rare disease affecting newborn babies
13 Mar 2014
A rare and potentially lethal disease of newborn babies whose bodies make too much insulin may be treatable with fish oils, according to researchers from The University of Manchester.
The disease, called congenital hyperinsulinism, means that the infant’s brain is starved of blood sugar which can lead to brain damage or long-term disability. But by giving the children purified fish oils similar to those used to treat some heart attack patients, alongside standard medical treatment, their blood sugar levels improve, the researchers reported today in the open-access journal Frontiers in Endocrinology.
Congenital hyperinsulinism - the clinical opposite of diabetes - is a rare disorder affecting roughly 1 in 50,000 children overall in the UK. It causes the child’s body to produce too much insulin, leading to frequent low blood sugar episodes.
Low blood sugar in the baby’s developing brain can lead to long term disabilities or brain damage, according to previous research carried out by the team.
Dr Karen Cosgrove, from the University's Faculty of Life Sciences who helped to carry out the new study, says: "Although we didn’t see enormous changes in our patients during the research, the effects were small but positive. It is important for all babies with congenital hyperinsulinism because it is a condition which is so difficult to treat.”
Researchers from The University of Manchester along with consultants from the Royal Manchester Children's Hospital part of Central Manchester University Hospitals NHS Foundation Trust, teamed up for the research. Royal Manchester Children's Hospital is the base for the Northern Congenital Hyperinsulinism (NorCHI) service which is a highly specialised service for the treatment of this condition.
"Our findings are paving the way for further research into how newer treatments can help to stabilise blood sugar levels in babies with congenital hyperinsulinism” says Dr Mars Skae, Consultant in Paediatric Endocrinology at Royal Manchester Children’s Hospital – and key member of the NorCHI team.
“The current medical treatment for children with congenital hyperinsulinism has been quite limited. The addition of this fish oil supplement may be a simple but effective way of treating low blood sugars in many children with this difficult condition” says Doctor Indi Banerjee, Consultant in Paediatric Endocrinology at Royal Manchester Children's Hospital and clinical lead for NORCHI.
Notes for editors
Media Relations Officer
Faculty of Life Sciences
The University of Manchester
Tel. +44 (0)161 275 2111
Congenital hyperinsulinism is much more common (1 in 2500 children) in Ashkenazi Jewish populations, in Saudi Arabia and some areas of Finland. It is also more common in children of consanguineous parents.
The paper is freely available at the following link: http://journal.frontiersin.org/Journal/10.3389/fendo.2014.00031/abstract
‘Reduced glycaemic variability in diazoxide-responsive children with
congenital hyperinsulinism using supplemental omega-3-polyunsaturated
fatty acids; a pilot trial with MaxEPA’ by Mars Skae, Hima Bindu Avatapalle, Indraneel (Indi) Banerjee, Lindsey Rigby, Andy Vail, Peter Foster, Christiana Charalambous, Louise Bowden, Raja Padidela, Leena Patel, Sarah Ehtisham, Karen Cosgrove, Mark Dunne and Peter Clayton.
Central Manchester University Hospitals NHS Foundation Trust is a leading provider of specialist healthcare services in Manchester, treating more than a million patients every year. Its eight specialist hospitals (Manchester Royal Infirmary, Saint Mary’s Hospital, Royal Manchester Children’s Hospital, Manchester Royal Eye Hospital, University Dental Hospital of Manchester and Trafford Hospitals) are home to hundreds of world class clinicians and academic staff committed to finding patients the best care and treatments. (www.cmft.nhs.uk)